Randomized, Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Idiopathic Pneumonia Syndrome After Allogeneic Stem Cell Transplantation: BMT CTN Protocol. Biol Blood Marrow Transplant, 20, 858-864. presented at the 06/2014. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/24607553. (2014).
A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results from CALGB 100103/BMT CTN 0502. In 54th Annual ASH Meeting. presented at the 08/12/2012, Atlanta, GA. Retrieved from http://www.hematology.org/Meetings/Annual-Meeting/. (2012).
Maximizing Accrual to Transplant Trials in Multiple Myeloma (MM): Lessons from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN), Eastern Cooperative Oncology Group (ECOG) and Cancer and Leukemia Group B (CALGB) Collaboration (Poster). In NCI ASCO Cancer Trials Accrual Symposium. presented at the 2010, Bethesda, MD.. (2010).
Blood and Marrow Transplant Clinical Trials Network Toxicity Committee Consensus Summary: Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant, 11, 571-575. presented at the 08/2005. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/16041306. (2005).